All In Biotech

Drug Trial Radar · NCT03363854

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

380

Actual

Start

Feb 22, 2018

Primary completion

Mar 8, 2019

Study completion Sep 26, 2019

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Dec 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared with placebo in combination with TCS. To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 32 weeks.

Conditions

  • Atopic Dermatitis

Interventions

  • TralokinumabDrug

    Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

  • PlaceboDrug

    Placebo contains the same excipients in the same concentration only lacking tralokinumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16Time frame: Week 16
  2. Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16Time frame: Week 16

Locations

66 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama-Birmingham

    Birmingham, Alabama

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • First OC Dermatology

    Fountain Valley, California

  • Center for Dermatology Clinical Research

    Fremont, California

  • Dermatology Research Associates

    Los Angeles, California

  • Clinical Science Institute

    Santa Monica, California

  • Danbury Clinical Research

    Danbury, Connecticut

  • International Dermatology Research

    Miami, Florida

  • L & C Professional Medical Research

    Miami, Florida

  • Lenus Research & Medical Group

    Sweetwater, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Medical Dermatology Specialists

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana Clinical Trials Center

    Plainfield, Indiana

  • Study Center

    Bangor, Maine

  • Respiratory Medicine Research

    Ypsilanti, Michigan

  • Mount Sinai West Dermatoogy

    New York, New York

  • Wake Research

    Raleigh, North Carolina

  • Dermatologists of Greater Columbus

    Bexley, Ohio

  • Oregon Dermatology & Research

    Portland, Oregon

  • National Allergy and Asthma Research, LLC

    North Charleston, South Carolina

  • University Hospital Antwerp

    Antwerp, Belgium

  • Universitair ziekenhuis Brussel

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • LEO Pharma Investigational Site

    Loverval, Belgium

  • Institute for Skin Advancement

    Calgary, Alberta, Canada

  • Skin Care Centre

    Vancouver, British Columbia, Canada

  • Maritime Medical Research Centre

    Bathurst, New Brunswick, Canada

  • Eastern Canada Cutaneous Research

    Halifax, Nova Scotia, Canada

  • CCA Medical Research

    Ajax, Ontario, Canada

  • Simcoderm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • DermEdge Research

    Mississauga, Ontario, Canada

  • York Dermatology Center

    Richmond Hill, Ontario, Canada

  • Research Toronto

    Toronto, Ontario, Canada

  • XLR8 Medical Research

    Windsor, Ontario, Canada

  • Interdisciplinary Study Association GmbH

    Berlin, Germany

  • St. Josef-Hospital, Ruhr-Universitet

    Bochum, Germany

  • Klinik und Poliklinik für Dermatologie und Allergologie

    Bonn, Germany

  • Klinikum der Johann Wolfgang Goethe-Universität Klinik

    Frankfurt am Main, Germany

  • MensingDerma Research GmbH

    Hamburg, Germany

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.